1. singh Ajit Pal
2. Nagpal Ankita

9789350252727

10.5005/jp/books/11216_7

1/e

2011

18

1. Panacea Biotech Ltd. India, B-1 Extn./G-3, Mohan Cooperative Industrial Estate, Mathura Road, New Delhi, India
2. Panacea Biotech Ltd. India, B-1 Extn./G-3, Mohan Cooperative Industrial Estate, Mathura Road, New Delhi, India

Vaccination, salk vaccine, immunogenicity, randomized controlled trials (RCT), booster vaccination, stratified randomization, demography, block randomization, superiority trial, placebo, serum creatinine, pulmonary function tests, hepatitis B, Haemophilus influenzae type b, diphtheria vaccine, surrogate end-point, vaccine immunogenicity studies, dose-response immunogenicity study, two-sided equivalence trials, non-polio acute flaccid paralysis, immunogenicity of the aP(2Fr) antigens, DTaP(2Fr) vaccine, Sénégal efficacy trial, FHA antigens, varicella zoster virus, chickenpox, enzyme-linked immunosorbent assay, immunofluorescence assay (IF)